Susan M. Domchek, MD
Executive Director, Basser Research Center
Director, MacDonald Women's Cancer Risk Evaluation Center
Abramson Family Cancer Center
University of Pennsylvania School of Medicine
2013-2014 BCRF Project:
(The Hard Rock Café International Award)
As part of their ongoing efforts to develop and test new immune therapies for patients with breast cancer, Drs. Domchek and Vonderheide have opened to two clinical trials this year, both of which are currently enrolling patients: (1) a novel peptide vaccine that targets the cancer proteins telomerase and survivin, and (2) genetically engineered T cells injected into the tumor and designed to destroy breast cancer cells expressing the c-Met target. These trials are being performed with state-of-the-art immune assessment assays to determine mechanism of action. In addition to continuing these trials in the coming year, the researchers will also design and implement a third clinical trial that targets telomerase using a next-generation gene therapy approach.
Dr. Susan Domchek was recently appointed the Executive Director of the newly founded Basser Research Center at the Abramson Family Cancer Center at the University of Pennsylvania. She is also the Basser Associate Professor in Oncology at the School of Medicine and directs the MacDonald Women's Cancer Risk Evaluation Center, which focuses on genetic evaluation and medical management of patients and individuals with BRCA1 and BRCA2 mutations and other inherited risk factors for cancer.
Dr. Domchek graduated from Dartmouth College and received her medical degree from Harvard Medical School. She completed her clinical training at the Massachusetts General Hospital as a resident in Internal Medicine and the Dana-Farber Cancer Institute as a fellow in Hematology and Oncology. She was chief resident in medicine at the Massachusetts General Hospital and joined the University of Pennsylvania faculty in 2001.
A member of the American Society of Clinical Oncology, Dr. Domchek was recognized as one of the Best Doctors in America, as well as in Philadelphia magazine's "Top Docs" edition, for the last two consecutive years.